173 related articles for article (PubMed ID: 34560682)
1. Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1.
Hackeng WM; van Beek DJ; Kok ASM; van Emst M; Morsink FHM; van Treijen MJC; Borel Rinkes IHM; Dreijerink KMA; Offerhaus GJA; Valk GD; Vriens MR; Brosens LAA
Am J Surg Pathol; 2022 Feb; 46(2):159-168. PubMed ID: 34560682
[TBL] [Abstract][Full Text] [Related]
2. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis.
Pieterman CR; Conemans EB; Dreijerink KM; de Laat JM; Timmers HT; Vriens MR; Valk GD
Endocr Relat Cancer; 2014 Jun; 21(3):R121-42. PubMed ID: 24389729
[TBL] [Abstract][Full Text] [Related]
3. PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG.
Conemans EB; Nell S; Pieterman CRC; de Herder WW; Dekkers OM; Hermus AR; van der Horst-Schrivers AN; Bisschop PH; Havekes B; Drent ML; Vriens MR; Valk GD
Endocr Pract; 2017 Jun; 23(6):641-648. PubMed ID: 28225311
[TBL] [Abstract][Full Text] [Related]
4. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features.
Anlauf M; Garbrecht N; Henopp T; Schmitt A; Schlenger R; Raffel A; Krausch M; Gimm O; Eisenberger CF; Knoefel WT; Dralle H; Komminoth P; Heitz PU; Perren A; Klöppel G
World J Gastroenterol; 2006 Sep; 12(34):5440-6. PubMed ID: 17006979
[TBL] [Abstract][Full Text] [Related]
5. A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression.
Fahrmann JF; Wasylishen AR; Pieterman CRC; Irajizad E; Vykoukal J; Murage E; Wu R; Dennison JB; Krishna H; Peterson CB; Lozano G; Zhao H; Do KA; Halperin DM; Agarwal SK; Blau JE; Del Rivero J; Nilubol N; Walter MF; Welch JM; Weinstein LS; Vriens MR; van Leeuwaarde RS; van Treijen MJC; Valk GD; Perrier ND; Hanash SM
J Clin Endocrinol Metab; 2021 Nov; 106(12):e4969-e4980. PubMed ID: 34318891
[TBL] [Abstract][Full Text] [Related]
6. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
[TBL] [Abstract][Full Text] [Related]
7. Biliary tree gastrinomas in multiple endocrine neoplasia type 1 syndrome.
Tonelli F; Giudici F; Nesi G; Batignani G; Brandi ML
World J Gastroenterol; 2013 Dec; 19(45):8312-20. PubMed ID: 24363522
[TBL] [Abstract][Full Text] [Related]
8. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.
Hermann G; Konukiewitz B; Schmitt A; Perren A; Klöppel G
Virchows Arch; 2011 Aug; 459(2):147-54. PubMed ID: 21739268
[TBL] [Abstract][Full Text] [Related]
9. Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas.
Hackeng WM; Schelhaas W; Morsink FHM; Heidsma CM; van Eeden S; Valk GD; Vriens MR; Heaphy CM; Nieveen van Dijkum EJM; Offerhaus GJA; Dreijerink KMA; Brosens LAA
Endocr Pathol; 2020 Jun; 31(2):108-118. PubMed ID: 32103422
[TBL] [Abstract][Full Text] [Related]
10. Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance.
Anlauf M; Perren A; Klöppel G
Pathobiology; 2007; 74(5):279-84. PubMed ID: 17890894
[TBL] [Abstract][Full Text] [Related]
11. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas.
Anlauf M; Perren A; Meyer CL; Schmid S; Saremaslani P; Kruse ML; Weihe E; Komminoth P; Heitz PU; Klöppel G
Gastroenterology; 2005 May; 128(5):1187-98. PubMed ID: 15887103
[TBL] [Abstract][Full Text] [Related]
12. Sonic hedgehog and pancreatic-duodenal homeobox 1 expression distinguish between duodenal and pancreatic gastrinomas.
Fendrich V; Ramerth R; Waldmann J; Maschuw K; Langer P; Bartsch DK; Slater EP; Ramaswamy A; Rothmund M
Endocr Relat Cancer; 2009 Jun; 16(2):613-22. PubMed ID: 19240184
[TBL] [Abstract][Full Text] [Related]
13. Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor.
Anlauf M; Enosawa T; Henopp T; Schmitt A; Gimm O; Brauckhoff M; Dralle H; Musil A; Hauptmann S; Perren A; Klöppel G
Am J Surg Pathol; 2008 Jul; 32(7):1101-5. PubMed ID: 18520436
[TBL] [Abstract][Full Text] [Related]
14. Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters.
van Beek DJ; Nell S; Verkooijen HM; Borel Rinkes IHM; Valk GD; ; Vriens MR; ;
Surgery; 2021 Apr; 169(4):963-973. PubMed ID: 33220975
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.
Sadowski SM; Pieterman CRC; Perrier ND; Triponez F; Valk GD
Endocr Relat Cancer; 2020 Jun; 27(6):R145-R161. PubMed ID: 32229700
[TBL] [Abstract][Full Text] [Related]
16. Assessment of ARX expression, a novel biomarker for metastatic risk in pancreatic neuroendocrine tumors, in endoscopic ultrasound fine-needle aspiration.
Hackeng WM; Morsink FHM; Moons LMG; Heaphy CM; Offerhaus GJA; Dreijerink KMA; Brosens LAA
Diagn Cytopathol; 2020 Apr; 48(4):308-315. PubMed ID: 31846235
[TBL] [Abstract][Full Text] [Related]
17. Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1.
Lairmore TC; Chen VY; DeBenedetti MK; Gillanders WE; Norton JA; Doherty GM
Ann Surg; 2000 Jun; 231(6):909-18. PubMed ID: 10816635
[TBL] [Abstract][Full Text] [Related]
18. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
[TBL] [Abstract][Full Text] [Related]
19. A personal experience with pancreatic and duodenal neuroendocrine tumors.
Jordan PH
J Am Coll Surg; 1999 Nov; 189(5):470-82. PubMed ID: 10549736
[TBL] [Abstract][Full Text] [Related]
20. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1.
Bartsch DK; Fendrich V; Langer P; Celik I; Kann PH; Rothmund M
Ann Surg; 2005 Dec; 242(6):757-64, discussion 764-6. PubMed ID: 16327485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
